SCHEMBL5606910

SCHEMBL5606910

CS(=O)(=O)NCc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.59
SLC7A5 Q01650 3/20 0.56
PTGS1 P23219 3/20 0.54
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
XIAP P98170 1/20 0.54
KDM4E B2RXH2 3/20 0.51
RECQL P46063 2/20 0.51
POLB P06746 1/20 0.51
TSHR P16473 1/20 0.51
TPH1 P17752 4/20 0.48
GRB2 P62993 1/20 0.48
ALOX15 P16050 3/20 0.47
HIF1A Q16665 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
USP2 O75604 1/20 0.47
EGFR P00533 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
ADORA3 P0DMS8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1595807 0.81 SLC7A5 (0.56) KMT2ASLC7A5PTGS1ALPIPKM
SCHEMBL1595806 0.81 SLC7A5 (0.56) KMT2ASLC7A5PTGS1ALPIPKM
SCHEMBL23659568 0.81 NPC1 (0.73) KMT2AKDM4ERECQLPOLBTSHR
Tyrosine SCHEMBL17874442 0.81 SLC7A5 (0.80) SLC7A5PTGS1ALPIPKMXIAP
Tyrosine SCHEMBL17874441 0.81 SLC7A5 (0.80) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL27754918 0.81 KEAP1 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL5607840 0.81 KEAP1 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL5608193 0.80 LMNA (0.62) KMT2APOLBTPH1TDP1USP2
SCHEMBL12611747 0.80 SLC7A5 (0.62) KMT2ASLC7A5PTGS1ALPIPKM
Phenylalanine SCHEMBL8610376 0.80 SLC7A5 (0.79) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP KMT2A 3688/4885SLC7A5 2674/4885PTGS1 1654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.